Our in vivo findings indicated that the overexpression of FBP1 could exert an anti-tumor effect on ovarian cancer cells and sensitize ovarian cancer cells to cisplatin treatment both in vitro and in vivo. This evidence concerns the gene FBP1 and ovarian carcinoma.